Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Biomolecules. 2021 Jul 1;11(7):973. doi: 10.3390/biom11070973.
Usnic acid (UA) is a secondary metabolite of lichens that exhibits a wide range of biological activities. Previously, we found that UA derivatives are effective inhibitors of tyrosyl-DNA phosphodiesterase 1 (TDP1). It can remove covalent complex DNA-topoisomerase 1 (TOP1) stabilized by the TOP1 inhibitor topotecan, neutralizing the effect of the drugs. TDP1 removes damage at the 3' end of DNA caused by other anticancer agents. Thus, TDP1 is a promising therapeutic target for the development of drug combinations with topotecan, as well as other drugs for cancer treatment. Ten new UA enamino derivatives with variation in the terpene fragment and substituent of the UA backbone were synthesized and tested as TDP1 inhibitors. Four compounds, -, had IC values in the 0.23-0.40 μM range. Molecular modelling showed that -, with relatively short aliphatic chains, fit to the important binding domains. The intrinsic cytotoxicity of - was tested on two human cell lines. The compounds had low cytotoxicity with CC ≥ 60 μM for both cell lines. and had high inhibition efficacy and low cytotoxicity, and they enhanced topotecan's cytotoxicity in cancerous HeLa cells but reduced it in the non-cancerous HEK293A cells. This "protective" effect from topotecan on non-cancerous cells requires further investigation.
乌头酸(UA)是一种地衣的次生代谢产物,具有广泛的生物活性。此前,我们发现 UA 衍生物是酪氨酸-DNA 磷酸二酯酶 1(TDP1)的有效抑制剂。它可以去除拓扑异构酶 1 抑制剂拓扑替康稳定的与 DNA 共价结合的拓扑异构酶 1(TOP1)复合物,中和药物的作用。TDP1 可去除其他抗癌药物引起的 DNA 3'末端损伤。因此,TDP1 是开发与拓扑替康以及其他癌症治疗药物联合用药的有前途的治疗靶点。我们合成并测试了十种具有萜烯片段和 UA 主链取代基变化的新型 UA 烯胺衍生物作为 TDP1 抑制剂。四种化合物(-)具有 0.23-0.40 μM 的 IC 值。分子建模表明,具有相对较短的脂肪链的 - 适合于重要的结合域。在两种人细胞系上测试了 - 的内在细胞毒性。对于两种细胞系,CC 均大于 60 μM,化合物的细胞毒性较低。和具有高抑制功效和低细胞毒性,它们增强了拓扑替康在癌细胞中的细胞毒性,但在非癌细胞 HEK293A 细胞中降低了它的细胞毒性。拓扑替康对非癌细胞的这种“保护”作用需要进一步研究。